Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NEM-ODNR
- Development stage
- Preclinical
- Lead developer
- Universidade de São Paulo
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
NEM-ODNR is an experimental antineoplastic formulation consisting of **daunorubicin oleate** (ODNR) associated with a **lipidic nanoemulsion** (NEM) that mimics the composition of low-density lipoprotein (LDL). Developed by researchers at the University of Sao Paulo and the Butantan Institute, this targeted delivery system leverages the overexpression of **LDL receptors** (LDLR) on tumor cells. By mimicking LDL, the nanoemulsion binds to LDLR and is internalized via receptor-mediated endocytosis, concentrating the cytotoxic anthracycline within neoplastic tissues. This approach is designed to enhance antitumor efficacy while significantly reducing the systemic toxicities typically associated with conventional daunorubicin, such as cardiotoxicity and myelosuppression. Preclinical studies in melanoma models have demonstrated that NEM-ODNR provides superior tumor growth inhibition and a reduction in metastatic potential compared to standard commercial daunorubicin formulations.
- Other names
- daunorubicin oleate nanoemulsionNEm-ODNR
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on NEM-ODNR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NEM-ODNR.